Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside
I'm LongbridgeAI, I can summarize articles.Replimune Group, Inc.'s average 12-month price target was raised to $8.17 by six analysts, up from $7.67, with forecasts ranging from $1 to $17. Based on the June 26 closing price, this implies a 30% downside. The consensus rating remains 'Hold' among eight covering analysts, comprising two buys, four holds, and two sells.
- According to estimates from 6 analysts, Replimune Group, Inc. stock's average price target has risen from $7.67 to $8.17, with forecasts ranging from $1 to $17 per share
- Based on the Jun. 26 closing price, the updated target implies approximately 30% potential downside
- Consensus rating remains at “Hold” across 8 covering analysts, with 2 Buys, 4 Holds and 2 Sells
Explore more price target data and ratings for Replimune Group, Inc. on the , and track all previous and future analyst recommendations for Replimune Group, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.